Comparison of the effect of ranibizumab and dexamethasone implant on serous retinal detachment in diabetic macular edema

Demircan, Ali; Özkaya, Abdullah; Alkın, Zeynep; Kemer, B.; Yeşilkaya, Ceren; Demir, Gökhan

doi:10.1016/j.jfo.2018.03.004

Cited by 10 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SRD was supposed to be an accumulation of edema in the subretinal space. [13][14][15] It may be easily detected via OCT. 15 The exact Figure 2. The consecutive optical coherence tomography images of two eyes from the study: (a-e) the baseline and month 3, 6, 9, and 12 optical coherence images of a patient who was treated with aflibercept and showed resolution of subfoveal retinal detachment at month 3; (f-j) the baseline and month 3, 6, 9, and 12 optical coherence images of a patient who was treated with ranibizumab and showed persistence of subfoveal retinal detachment and diabetic macular edema at all of the time points (the height of SRD was measured with the built-in caliper fundus of the optical coherence tomography device).…”

Section: Discussionmentioning

confidence: 99%

“…As discussed above, there are a few studies comparing the effectiveness of the anti-VEGF drugs in patients with DME; in addition, the literature data are scarce in regards to the outcomes of anti-VEGF treatment in DME patients associated with SRD. 8,9,13,18,21,22 Kaya et al 18 evaluated the efficacy of IVR in DME in a retrospective case series. The included 134 eyes were classified into three subgroups which were SRD, diffuse retinal thickness, and cystoid macular edema.…”

Section: Discussionmentioning

confidence: 99%

“…Perhaps, this was the cause of our better visual outcomes. In a recent study by Demircan et al, 13 the early outcomes of intravitreal dexamethasone implant and IVR were compared in DME patients associated with SRD. The visual outcomes were similar between the two groups.…”

Section: Discussionmentioning

confidence: 99%

“…SRD was supposed to be an accumulation of edema in the subretinal space. 13–15 It may be easily detected via OCT. 15 The exact mechanism and pathophysiology of SRD have not been clearly determined yet. 15 It was thought to have occurred secondary to excessive leakage from retinal and choroidal circulation.…”

Section: Discussionmentioning

confidence: 99%

“…As expected, the dexamethasone implant showed better resolution of SRD in the early treatment period. 13 In the light of the studies regarding the role of PGF in inflammation and the relationship with inflammation and SRD, we planned this study, to compare the efficacy of aflibercept and ranibizumab in patients with DME associated with SRD.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment

Özkaya

Demir

Kirmaci

2019

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To compare the efficacy of ranibizumab and aflibercept in the treatment of diabetic macular edema associated with subfoveal retinal detachment. Methods: This is a retrospective, comparative study. The treatment-naïve diabetic macular edema patients who had diabetic macular edema associated with subfoveal retinal detachment and underwent intravitreal aflibercept or intravitreal ranibizumab treatment were included. The patients were treated on a pro re nata treatment regimen after a loading dose of 3-monthly injections and the follow-up time was 12 months. The primary outcome measure of this study was the presence of subfoveal retinal detachment after treatment at different time points. The secondary outcome measures were the change in best corrected visual acuity and central retinal thickness. Results: A total of 46 eyes of 46 patients were included. The aflibercept group consisted of 20 and the ranibizumab group consisted of 26 eyes. During the follow-up period of 12 months, subfoveal retinal detachment was completely resolved in 75% versus 57.7% of the eyes at month 3 (p = 0.2), 90% versus 76.9% at month 6 (p = 0.2), 90% versus 65.4% at month 9 (p = 0.05), and 100% versus 80.8% at month 12 (p = 0.03) in the intravitreal aflibercept versus intravitreal ranibizumab groups. The change in best corrected visual acuity was not statistically different between the groups at months 3, 6, 9, and 12, respectively (p > 0.05 for all). Conclusion: Both intravitreal aflibercept and intravitreal ranibizumab were effective in regards to anatomical and functional outcomes of diabetic macular edema patients associated with subfoveal retinal detachment. Interestingly, intravitreal aflibercept seemed more effective than intravitreal ranibizumab in the resolution of subfoveal retinal detachment at month 12.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment

Özkaya

Demir

Kirmaci

2019

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis

Chi

Kang

Huang

2023

Sci Rep

View full text Add to dashboard Cite

To better understand the efficacy of intravitreal dexamethasone implant (Ozurdex) versus antivascular endothelial growth factor (anti-VEGF) treatment in patients with diabetic macular edema (DME). A systematic review and meta-analysis. The study included randomized control trials (RCTs) and non-randomized control trials (Non-RCTs) before December 2021 that compare the efficacy of Ozurdex-related therapyand anti-VEGF therapy. We searched PubMed, Cochrane Library, and EMBASE. The quality of the included studies was assessed carefully. 30 studies were included. Regarding BCVA change, the overall result revealed no significant differences between Ozurdex and anti-VEGF therapies in patients with nonresistant DME, but Ozurdex group had significantly more VA improvement than anti-VEGF therapies in patients with resistant DME (MD 0.12, 95% CI 0.02–0.21). In terms of central retinal thickness (CRT) decrease, there was a significant difference between Ozurdex therapy and anti-VEGF therapy in patients with nonresistant DME (MD 48.10, 95% CI 19.06–77.13) and resistant DME (MD 65.37, 95% CI 3.62–127.13). Overall, Ozurdex therapy resulted in significantly greater VA improvement and CRT decrease than anti-VEGF therapy in resistant DME patients. Ozurdex therapy was not inferior to anti-VEGF therapy in patients with nonresistant DME.

show abstract

Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema

Bölükbaşı

Çakir

Erden

et al. 2019

Cutaneous and Ocular Toxicology

View full text Add to dashboard Cite

Comparison of the effect of ranibizumab and dexamethasone implant on serous retinal detachment in diabetic macular edema

Cited by 10 publications

References 24 publications

Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment

Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment

Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis

Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema

Contact Info

Product

Resources

About